Quanticel Pharmaceuticals Acquired By Celgene

San Diego- and San Francisco-based Quanticel Pharmaceuticals has been acquired Celgene, in a deal worth $100M in cash plus up to $385M in earn out. Celgene said the deal gives it access to Quanticel's proprietary platform for the single-cell genomic analysis of human cancer, to help advance Celgene's pipeline of cancer therapies. Quanticel had been led by Steve Kaldor, and was venture backed by Versant Ventures.